Advertisement
UK markets close in 2 hours 39 minutes
  • FTSE 100

    8,351.94
    -64.51 (-0.77%)
     
  • FTSE 250

    20,688.94
    -94.43 (-0.45%)
     
  • AIM

    805.59
    -1.50 (-0.19%)
     
  • GBP/EUR

    1.1743
    +0.0037 (+0.32%)
     
  • GBP/USD

    1.2726
    +0.0015 (+0.11%)
     
  • Bitcoin GBP

    54,789.02
    -1,238.01 (-2.21%)
     
  • CMC Crypto 200

    1,513.42
    -12.99 (-0.85%)
     
  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     
  • DOW

    39,872.99
    +66.22 (+0.17%)
     
  • CRUDE OIL

    77.98
    -0.68 (-0.86%)
     
  • GOLD FUTURES

    2,414.10
    -11.80 (-0.49%)
     
  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     
  • HANG SENG

    19,195.60
    -25.02 (-0.13%)
     
  • DAX

    18,655.72
    -71.04 (-0.38%)
     
  • CAC 40

    8,079.59
    -61.87 (-0.76%)
     

Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

ReportLinker
ReportLinker

Summary. This reports provides a data-driven overview of the current and future competitive landscape in AS therapeutics. - There will be more than 313,981 diagnosed prevalent cases of AS in 2023 in the 16 major markets.

New York, May 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06454299/?utm_source=GNW


Summary
This reports provides a data-driven overview of the current and future competitive landscape in AS therapeutics.

- There will be more than 313,981 diagnosed prevalent cases of AS in 2023 in the 16 major markets.
- The marketed drugs space for AS is poor as there are no therapies currently approved for the treatment of the disease.
- R&D activity in AS is very sparse, with only one drug in late-stage development.
- Commercial sponsors dominated the clinical trials space in AS over the past 10 years, with Ovid Therapeutics sponsoring the highest number of clinical trials.
- During the past 12 months, three merger and acquisition transactions involving companies developing AS assets were successfully completed.

Scope
Angelman Syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06454299/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001